Investigational drug · Phase 3
GM1
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: May 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
41
Any phase or sponsor naming "GM1"
First trial start
2025
Aug 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GM1", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chemotherapy-induced Peripheral Neuropathy (CIPN)
- Parkinson's Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "GM1" as an intervention, largest first.
- Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory StudyPivotal-lookingCompleted
Qilu Pharmaceutical Co., Ltd.Industry
NCT06742216 · 1,232 participants · Start Nov 3, 2020 · Primary completion Aug 30, 2023
Drug: Monosialoganglioside; Placebo · For: Acute Ischemic Stroke
Sites: Nanjing, China
- Safety and Efficacy of Adjunctive GM1 to Mechanical Thrombectomy for Acute Anterior Circulation Large Vessel OcclusionPivotal-lookingRecruiting
Xuanwu Hospital, BeijingAcademic, hospital or other
NCT07519044 · 868 participants (planned) · Start May 14, 2026 · Primary completion Jan 31, 2027
Drug: Intravenous GM1 Therapy; Placebo Therapy · For: Stroke; Acute Ischemic Stroke
Sites: Beijing, China; Shandong, China
- GM1 Prophylaxis for Nab-paclitaxel-associated Chemotherapy-induced Peripheral Neuropathy (CIPN) in Patients With Breast CancerPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06994507 · 352 participants (planned) · Start Aug 1, 2025 · Primary completion Sep 2026
Drug: GM1; Placebo · For: Chemotherapy-induced Peripheral Neuropathy (CIPN)
Sites: Beijing, China
- Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC PatientsPivotal-lookingStatus unknown
Sun Yat-sen UniversityAcademic, hospital or other
NCT01882621 · 300 participants (planned) · Start Oct 2013 · Primary completion Aug 2016
Drug: Monosialoganglioside(GM1); normal saline · For: Non-small Cell Lung Cancer
Sites: Guangzhou, China
- An Exploratory Study of Ganglioside GM1 in Acute Ischemic StrokePivotal-lookingCompleted
General Hospital of Shenyang Military RegionAcademic, hospital or other
NCT04952064 · 300 participants · Start Jul 28, 2021 · Primary completion Jul 18, 2022
Drug: Monosialoganglioside GM1 · For: Stroke, Ischemic
Sites: Shenyang, China
- A Study to Evaluate the Efficacy and Safety of Monosialotetrahexosylganglioside Sodium Injection in Parkinson's Disease Participants With Motor FluctuationsPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07585565 · 276 participants (planned) · Start May 2026 · Primary completion Mar 2028
Drug: GM1; GM1 and 4 more · For: Parkinson's Disease
- BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)Pivotal-lookingActive, not recruiting
SCRI Development Innovations, LLCAcademic, hospital or other
NCT06773910 · 250 participants (planned) · Start Mar 11, 2025 · Primary completion May 2032
Drug: BMS-986489; Durvalumab · For: Limited Stage Small Cell Lung Cancer
Sites: Daphne, Alabama; Santa Barbara, California; Fort Myers, Florida · 34 sites in all
- Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRCPivotal-lookingStatus unknown
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT02024412 · 240 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: monosialotetrahexosylganglioside Sodium · For: Colorectal Cancer
Sites: Tianjin, China
- Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric CancerPivotal-lookingStatus unknown
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT02024438 · 240 participants (planned) · Start Dec 2013 · Primary completion Dec 2016
Drug: monosialotetrahexosylganglioside Sodium · For: Gastric Cancer
Sites: Tianjin, China · 2 sites in all
- Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal DisordersPivotal-lookingNot yet recruiting
Azafaros B.V.Industry
NCT07885917 · 218 participants (planned) · Start Dec 10, 2026 · Primary completion Apr 1, 2030
Drug: AZ-3102 · For: Niemann-Pick Disease Type C; GM2 Gangliosidosis; GM1 Gangliosidosis and 1 more
Newest research
PubMed records naming it or its code names, newest first.
- Restoration of BDNF/TrkB signaling rescues presynaptic dysfunction in GM1 gangliosidosis iPSC-derived neurons.
Numakawa T, Kajihara R, Horita C, et al. · Biochem Biophys Res Commun 2026
- IFITM1-mediated restriction of henipavirus entry is associated with ephrinB2 reorganization and confinement in membrane nanodomains.
Luo Y, Wang J, Li J, et al. · Proc Natl Acad Sci U S A 2026
- Type II GM1 Gangliosidosis with Intrafamilial Variability: A Case Series of Five Affected Siblings.
Soni P, Vaidya A, Darshan M, et al. · J Appl Genet 2026
- Dual-glycolipid engineered vaccine platform empowers delivery route customization to intercept tumor lung metastasis.
Wei L, Xu W, Zhang T, et al. · J Control Release 2026
- High glucose with insulin signalling blockade promotes cholesterol-sensitive, FAK-dependent UPEC invasion and blunts bladder antimicrobial defence.
Maurya S, Monika, Thapa J, et al. · Biochem Biophys Res Commun 2026
- Production and characterization of green and biodegradable pectin and whey protein isolate edible films.
Kavrut E · J Food Sci Technol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.